Get started

EGX100

BICO risen from 27 to 41 in 5 monthsRapid change with almost certain assistance from its parent company What happened during the past period is like a miracle. The company transformed after the first quarter results showed huge losses and embezzlement charges that resulted in restructuring. After the distribution of closed dividends per share was suspended at 0.75 until liquidity was available, and liquidity was available quickly. I believe that financing was provided by the parent company in exchange for an export share and benefiting from the currency difference after the delay in the Medicine Authority’s decision to move the exchange rate. The pending dividends were issued to shareholders and we await the second-quarter results, which look promising I expect the stock to rise to 30 pounds during the month of 8, and the trend is towards 40 in January 2025.
EGX:BIOCLong
by atuumra
Egyptian Drug Authority and Pharmaceutical CompaniesEbeco Company is one of the leading pharmaceutical companies in Egypt, with a long history of manufacturing and exporting medicines. Over the past two years, the company has benefited from therapeutic supply contracts to African countries through the United Nations and the African Union, which has led to significant growth in its revenues and profits. Negative Impacts: However, the company has faced some challenges in the Egyptian market over the past seven months due to the implementation of maximum price caps for medicines by the Egyptian Drug Authority. This decision has particularly affected Ebeco, as most of its profitable medicines are antibiotics and cough syrups, which are categories of medicines that have been included in the price cap. Positive Impacts: Despite these challenges, Ebeco has been able to compensate for some of its losses by expanding its operations into Central African markets through international export companies. Short-Term Outlook: In the short term, Ebeco's share price is expected to move in a trading range between 32 and 48 Egyptian pounds. This is due to investors waiting for the Egyptian Drug Authority's approval of requests from pharmaceutical companies to raise their prices. Future Scenarios: In case of approval to raise prices: Share prices of all pharmaceutical companies are expected to rise significantly, in line with the percentage allowed for price increases. This will lead to an improvement in Ebeco's financial performance and attract more investors to the stock. In case of rejection by the Egyptian Drug Authority of requests to raise prices: The scenario of a decline in the share price and a continued trading range is likely to continue until a new development occurs. The company may face further challenges in the Egyptian market, which could negatively impact its financial performance.
EGX:PHAR
by atuumra
Is The Market Ready to Bounce?- EGX100 is down around 27% from its high. - Today it hit a very important level, the 200 day MA which was tested before on March 2023, and also if we measure the fib level, we find that it retraced to a 50% level. - This also occurs while EGX30 hitting its 200 day MA as well. - Now we can never know for sure if this bottom or not, but we can be prepared for both scenarios. - Resistance overhead @ 8500 if this can be breached, the way is clear towards the 9000 level, and this a very critical level, as anywhere between 8500/9000 the sellers may show up again and try to push the market down. - If buyers manage to break the 9000 level, the probability that this is a bottom is high, with only the level between 9300-9700 will be left to confirm the continuation of the bull trend. - Pls note that currently the market is considered on a downtrend with 20/50/100 MA all pointing down. - Not a good advice to reenter those tickers that became so cheap, look for the ones that were holding their levels as those are the ones with higher strength comparing to the market. - It's always better and safer to wait until the market confirms the bull trend before buying.
E
by ImSamTrades